346例脑梗死患者静脉用药的相关因素分析  

Analysis on Relevant Factors of Intravenous Medication in 346 In-patients with Cerebral Infarction

作　　者：秦媛媛[1] 黄玉宇[1] 沈夕坤[1] 朱荣荣[1] 

机构地区：[1]苏州市中医医院药学部,江苏苏州215009

出　　处：《抗感染药学》2016年第6期1237-1241,共5页Anti-infection Pharmacy

摘　　要：目的:分析346例脑梗死患者静脉用药情况,为脑梗死患者合理选用静脉用药物提供参考。方法:选取2012年1月—2013年2月间医院脑病科收治的脑梗死患者346例病历资料,统计患者的基本信息和静脉用药情况,以限定日剂量(DDD)计算用药频度(DDDs)和日均费用(DDDc)。结果:346例脑梗死患者静脉用药金额排序前3位的药物类型为中枢神经系统药物、中成药和抗感染药物,其中奥扎格雷钠在脑梗死患者静脉用药金额排序中居第3位,其DDDs排序靠前,具有疗效好、用药金额在患者可接受范围内和经济学属性佳的特点;乙酰谷酰胺的DDDs值为最大,DDDc值为最小,该药的经济学和药物治疗学属性均较为理想,为医院最常用的脑梗死患者辅助治疗药物;依达拉奉的用药金额、DDDc排序均居第1位,其用于治疗脑梗死的疗效较为显著,但经济学属性欠佳;单唾液酸四己糖神经节苷脂的用药金额、DDDs排序均居第2位,其DDDc值较大,价格较高,药物经济学属性不佳。结论:346例脑梗死患者的总有效率为97.11%,提示治疗用药和病情基本匹配,但由于脑梗死患者病情的复杂性,需多种药物联用治疗,因此临床应根据患者的疾病特点,合理选用静脉用药物。Objective： To analyse the relevant factors of intravenous medication in 346 in-patients with cerebral infarction and to provide a reference of rational intravenous medication in patients with cerebral infarction. Methods： 346 cases of cerebral infarction patients treated in encephalopathy department during January 2012 to February 2012 were selected, and the patients＇ basic information and intravenous drug usage status were collected. Thus DDDs （frequency of durg use） and DDDc （average daily costs） were counted based on defined daily dose （DDD）. Results： The TOP three of intravenous drugs used by 346 cerebral infarction patients were central nervous system drugs, chinese patent medicines and anti-infective drugs, from which ozagrel sodium was in the 3rd place, whose DDDs are sequenced front; morever it has good curative effect,and its amount was within patients acceptable range and so it has good economics characteristics.Aceglutamide＇s DDDs were supreme,while its DDDc was minimum, and its pharmacotherapeutics and drug economics attribute was relatively good, so it was the most commonly used cerebral infarction auxiliary drug in hospital.Edaravone＇s amout and DDDc sorted first, and its curative effect of cerebral infarction was significant, but its economic property was bad.Mono.sialoteterahexosyl ganglioside＇s amount and DDDs ranked 2nd, however its DDDc was high,and it has high price and poor pharmacoeconomics property. Conclusion： 346 cerebral infarction patients＇ cured（or recovery） rate was 97.11 percent, implying that treatment drugs and condition were basically matched.However the cerebral infarction condition was so complex that various drugs should be combined in use; thus appropriate drugs should be chosen according to patients＇ disease features.

关 键 词：脑梗死 静脉用药 分析 

分 类 号：R969.3[医药卫生—药理学]